ReviewMetabolites2021
Exploring the Gut Microbiota and Cardiovascular Disease.
Review in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- The Association between Gallstone Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis.Reviews on recent clinical trials · 2025Pooled it
- Effects of fecal microbiota transfer on blood pressure in animal models: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Gut Microbiota-Derived Metabolites and Cardiovascular Disease Risk: A Systematic Review of Prospective Cohort Studies.Nutrients · 2022Pooled it
- Review
- Gut microbiota-associated leucine elevation promotes cold-induced atherosclerotic plaque formation and instability.Journal of translational medicine · 2026Article
- Gut Microbiota as an Innovative Therapeutic Target in Cardiovascular Diseases from a Metabolic and Inflammatory Perspective.Biomedicines · 2026Review
- Gut Microbial Diversity and Community Structure Are Largely Similar Between Apparently Healthy Elderly Japanese Males and Females: A Shotgun Metagenomic Study.Life (Basel, Switzerland) · 2026Article
- Intestinal Microbiota in Early Life: Latest Findings Regarding the Role of Probiotics as a Treatment Approach for Dysbiosis.Nutrients · 2025Review
- The Interplay Between Nutrition and Microbiota and the Role of Probiotics and Symbiotics in Pediatric Infectious Diseases.Nutrients · 2025Review
- Operationalizing Team Science at the Academic Cancer Center Network to Unveil the Structure and Function of the Gut Microbiome.Journal of clinical medicine · 2025Review
- Gut Microbiome and Cardiovascular Health: Mechanisms, Therapeutic Potential and Future Directions.Heart international · 2025Review
- The Interplay of Diet, Genome, Metabolome, and Gut Microbiome in Cardiovascular Disease: A Narrative Review.Current medicinal chemistry · 2025Review
- Effects of Marine-Derived Components on Cardiovascular Disease Risk Factors and Gut Microbiota Diversity.Marine drugs · 2024Review
- Role of Gut Microbial Metabolites in Cardiovascular Diseases-Current Insights and the Road Ahead.International journal of molecular sciences · 2024Review
- Intestinal fatty acid binding protein is associated with infarct size and cardiac function in acute heart failure following myocardial infarction.Open heart · 2024Article
- Thrombosis and Thrombotic Risk in Athletes.Journal of clinical medicine · 2024Review
- The central executive network moderates the relationship between posttraumatic stress symptom severity and gastrointestinal related issues.Scientific reports · 2024Article
- A Mendelian Randomization Study: Roles of Gut Microbiota in Sepsis - Who is the Angle?Polish journal of microbiology · 2024Article
- Role of the intestinal microbiome and its therapeutic intervention in cardiovascular disorder.Frontiers in immunology · 2024Review
- Bile Acids and Short-Chain Fatty Acids Are Modulated after Onion and Apple Consumption in Obese Zucker Rats.Nutrients · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Cardiovascular disease (CVD) has been classified as one of the leading causes of morbidity and mortality worldwide. CVD risk factors include smoking, hypertension, dyslipidaemia, obesity, inflammation and diabetes. The gut microbiota can influence human health through multiple interactions and community changes are associated with the development and progression of numerous disease states, including CVD. The gut microbiota are involved in the production of several metabolites, such as short-chain fatty acids (SCFAs), bile acids and trimethylamine-N-oxide (TMAO). These products of microbial metabolism are important modulatory factors and have been associated with an increased risk of CVD. Due to its association with CVD development, the gut microbiota has emerged as a target for therapeutic approaches. In this review, we summarise the current knowledge on the role of the gut microbiome in CVD development, and associated microbial communities, functions, and metabolic profiles. We also discuss CVD therapeutic interventions that target the gut microbiota such as probiotics and faecal microbiota transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.